STCube Inc (052020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, STCube Inc (052020) has a cash flow conversion efficiency ratio of -0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.11 Billion ≈ $-2.79 Million USD) by net assets (₩65.58 Billion ≈ $44.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of STCube Inc to measure how many days the company can operate on defensive assets alone.
STCube Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how STCube Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
STCube Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STCube Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SR Accord
TA:SRAC
|
-0.112x |
|
QuantumSi Inc
NASDAQ:QSI
|
-0.128x |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
0.031x |
|
Kore Potash Plc
AU:KP2
|
-0.004x |
|
UniTest Incorporation
KQ:086390
|
-0.085x |
|
Atomera Inc
NASDAQ:ATOM
|
-0.175x |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
-0.001x |
|
Goknur Gida Maddeleri Enerji Imalati Ithalat Ihracat Ticaret ve Sanayi A.S.
IS:GOKNR
|
0.004x |
Annual Cash Flow Conversion Efficiency for STCube Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of STCube Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 052020 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩72.12 Billion ≈ $48.88 Million |
₩-19.78 Billion ≈ $-13.40 Million |
-0.274x | -10.84% |
| 2024-12-31 | ₩94.28 Billion ≈ $63.89 Million |
₩-23.32 Billion ≈ $-15.80 Million |
-0.247x | +64.51% |
| 2023-12-31 | ₩35.31 Billion ≈ $23.93 Million |
₩-24.61 Billion ≈ $-16.68 Million |
-0.697x | -121.89% |
| 2022-12-31 | ₩51.22 Billion ≈ $34.71 Million |
₩-16.09 Billion ≈ $-10.90 Million |
-0.314x | +70.39% |
| 2021-12-31 | ₩16.16 Billion ≈ $10.95 Million |
₩-17.15 Billion ≈ $-11.62 Million |
-1.061x | -271.33% |
| 2020-12-31 | ₩36.03 Billion ≈ $24.41 Million |
₩-10.29 Billion ≈ $-6.97 Million |
-0.286x | -4165.71% |
| 2019-12-31 | ₩28.82 Billion ≈ $19.53 Million |
₩-192.99 Million ≈ $-130.79K |
-0.007x | +95.65% |
| 2018-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.154x | +74.13% |
| 2017-12-31 | ₩19.12 Billion ≈ $12.96 Million |
₩-11.38 Billion ≈ $-7.71 Million |
-0.595x | -386.91% |
| 2016-12-31 | ₩29.24 Billion ≈ $19.81 Million |
₩6.07 Billion ≈ $4.11 Million |
0.207x | +203.54% |
| 2015-12-31 | ₩20.91 Billion ≈ $14.17 Million |
₩-4.19 Billion ≈ $-2.84 Million |
-0.200x | -182.38% |
| 2012-12-31 | ₩8.79 Billion ≈ $5.96 Million |
₩2.14 Billion ≈ $1.45 Million |
0.243x | +203.88% |
| 2011-12-31 | ₩9.97 Billion ≈ $6.76 Million |
₩-2.33 Billion ≈ $-1.58 Million |
-0.234x | -74.55% |
| 2010-12-31 | ₩11.74 Billion ≈ $7.95 Million |
₩-1.57 Billion ≈ $-1.07 Million |
-0.134x | -244.26% |
| 2009-12-31 | ₩16.63 Billion ≈ $11.27 Million |
₩1.55 Billion ≈ $1.05 Million |
0.093x | -- |
About STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more